Partial clinical response to anakinra in severe palmoplantar pustular psoriasis

British Journal of Dermatology

Volumn 171, Issue 3, 2014, Pages 646-649

  Tauber, M ^a   Viguier, M ^a   Alimova, E ^a   Petit, A ^a   Liote F ^b   Smahi, A ^a   Bachelez, H ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIPSORIASIS AGENT; CALCIPOTRIOL; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RETINOID; STEROID; USTEKINUMAB; DERMATOLOGICAL AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIOLOGICAL THERAPY; CASE REPORT; DEPRESSION; DESQUAMATION; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; MALE; MIDDLE AGED; PALMOPLANTAR PSORIASIS AREA AND SEVERITY INDEX; PALMOPLANTAR PUSTULAR PSORIASIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUSTULE; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; RATING SCALE; SALVAGE THERAPY; SKIN DEFECT; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; PSORIASIS;

AGED; DERMATOLOGIC AGENTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PSORIASIS; TREATMENT OUTCOME;

EID: 84925331152     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.13012     Document Type: Article

References (17)

1. Marsland AM, Chalmers R, Hollis S, et al,. Interventions for chronic palmoplantar pustulosis. Cochrane Database Syst Rev 2006; 1: CD001433.
2. Yawalkar N, Hunger RE,. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology 2009; 218: 79-83.
3. Morales-Múnera C, Vilarrasa E, Puig L,. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis. Br J Dermatol 2013; 168: 820-4.
4. Aksentijevich I, Masters SL, Ferguson PJ, et al,. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-37.
5. Viguier M, Guigue P, Pages C, et al,. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010; 153: 66-7.
6. Hüffmeier U, Wätzold M, Mohr J, et al,. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2014; 170: 202-4.
7. Rossi-Semerano L, Piram M, Chiaverini C, et al,. First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra. Pediatrics 2013; 132: e1043-7.
8. Lutz V, Lipsker D,. Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of Hallopeau responsive to the interleukin 1 receptor antagonist anakinra. Arch Dermatol 2012; 148: 297-9.
9. Bhushan M1, Burden AD, McElhone K, et al,. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001; 145: 546-53.
10. Marrakchi S, Guigue P, Renshaw BR, et al,. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
11. Setta-Kaffetzi N, Navarini AA, Patel VM, et al,. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol 2013; 133: 1366-9.
12. Pettey AA, Balkrishnan R, Rapp SR, et al,. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003; 49: 271-5.
13. Erkko P, Granlund H, Remitz A, et al,. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998; 139: 997-1004.
14. Gerdes S, Franke J, Domm S, et al,. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163: 1116-18.
15. Dinarello CA,. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-32.
16. Shepherd J, Little MC, Nicklin MJ,. Psoriasis-like cutaneous inflammation in mice lacking interleukin-1 receptor antagonist. J Invest Dermatol 2004; 122: 665-9.
17. Balato A, Schiattarella M, Lembo S, et al,. Interleukin-1 family members are enhanced in psoriasis and suppressed by vitamin D and retinoic acid. Arch Dermatol Res 2013; 305: 255-62.